Results 41 to 50 of about 1,327 (186)
Evaluating and Comparing the Safety and Efficacy of Rimegepant Versus Lasmiditan in Aborting Acute Migraine Headaches in the Adult Migraineur [PDF]
, 2023 Migraine headaches are one of the most common causes of primary headaches. Worldwide, migraines are one of the leading causes of disability and while the mechanism of migraines are not entirely understood, they result in significant disability for those ...
Douthit, Anthony
core +4 more sources
Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway [PDF]
, 2023 BACKGROUND: New acute and preventive migraine medications are available, but data on current treatment patterns are limited. This study describes migraine treatment patterns among patients initiating novel acute migraine specific medications (nAMSMs ...
Bensink, Mark E +9 more
core +2 more sources
Is rimegepant an effective treatment for acute migraine pain in adults? [PDF]
, 2022 OBJECTIVE: The objective of this selective EBM review is to determine whether or not “Is rimegepant an effective treatment for acute migraine pain in adults?” STUDY DESIGN: A systematic review of three, peer-reviewed randomized placebo-controlled trials (
Wright, Hanson S
core +1 more source
Rimegepant in the Treatment of Migraine
Archives of Internal Medicine Research, 2020 Migraine is a common and chronic disorder with significant financial and socioeconomic burden. It is the 2nd most common reason for the years lived with disability after back pain. Current available treatment of migraine is limited to subpopulation due to poor tolerability, efficacy, side effects, contraindication and drug-drug interactions.
Muhammad Adnan Haider +5 more
openaire +1 more source
Lasmiditan: the first neurally acting anti-migraine drug [PDF]
, 2021 Lasmiditan is the first neurally acting drug for the treatment of acute migraine. It is a highly selective, orally acting 5-HT1F agonist that was approved in November 2019, for the acute treatment of migraine in adults, with or without aura, by USFDA ...
Bhanwra, Sangeeta +2 more
core +2 more sources
ICER’s assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine [PDF]
Journal of Managed Care & Specialty Pharmacy, 2020 DISCLOSURES: No funding supported the writing of this commentary. The authors have nothing to disclose.
Meg, Franklin, Eric, Druyts
openaire +2 more sources
National Journal of Physiology, Pharmacy and Pharmacology, 2023 Background: Two new classes of drugs approved by USFDA for the treatment of acute migraine are non-peptide Calcitonin Gene-Related Peptide (CGRP) receptor antagonists (rimegepant and ubrogepant) and 5-HT1F receptor agonist lasmiditan.
Sharanabasayyaswamy Basayya Hiremath +1 more
doaj +1 more source
The Journal of Headache and Pain, 2022 Background In the absence of head-to-head trials, comprehensive evidence comparing onset of efficacy of novel agents for acute treatment of migraine is lacking.
Pepa Polavieja +4 more
doaj +1 more source
Efficacy of Rimegepant Plus Calcitonin Gene-Related Peptide Monoclonal Antibody for Migraine [PDF]
, 2021 Migraine is a paroxysmal pain disorder managed with abortive therapy during a pain attack, prophylactic therapy to prevent attacks, and often a combination of both. Calcitonin gene-related peptide (CGRP) and its receptor have a role in the provocation of
Leggio, Carina
core +1 more source
The Journal of Headache and Pain, 2022 Background The objective of this study was to describe patterns in monthly migraine days (MMD) and tablet utilization, and to estimate health-related quality of life (HRQoL) measures in patients treated as needed (PRN) with rimegepant 75 mg over 52-weeks.
Karissa Johnston +6 more
doaj +1 more source